Trial Outcomes & Findings for A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (NCT NCT05267470)

Last Updated: 2025-03-25

Results Overview

DLTs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and included the below if considered by the investigator to be related to study drug, excluding toxicities related to disease progression or intercurrent illness: Grade 3 thrombocytopenia for \> 7 days or with Grade \> 2 bleeding, vomiting/diarrhea for \> 3 days, fatigue; Grade ≥ 3 febrile neutropenia, nausea for \> 3 days; Grade 4 neutropenia, thrombocytopenia, anemia, ophthalmologic AE, laboratory value, vomiting/diarrhea; Grade 5 toxicity (death not due to disease progression). CTCAE Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 results in death.

Recruitment status

TERMINATED

Study phase

PHASE1

Target enrollment

74 participants

Primary outcome timeframe

Day 1 to Day 21 of Cycle 1 (each cycle was 21 days)

Results posted on

2025-03-25

Participant Flow

A total of 74 participants were enrolled across 8 countries from March 2022 and the last participant last visit was in May 2024.

The study consisted of 4 Parts: * Part 1: Combination dose exploration with docetaxel * Part 2: Combination dose expansion with docetaxel * Part 3: Monotherapy * Part 4: Combination with carboplatin, paclitaxel or nab-paclitaxel, and pembrolizumab. The planned dose levels were dose level 1 (lower) and dose level 2 (higher).

Participant milestones

Participant milestones
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel Participants received multiple intravenous (IV) doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 2: Bemarituzumab Dose 2 With Docetaxel Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Overall Study STARTED	4	9	29	28	4
Overall Study COMPLETED	0	0	0	0	0
Overall Study NOT COMPLETED	4	9	29	28	4

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel Participants received multiple intravenous (IV) doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 2: Bemarituzumab Dose 2 With Docetaxel Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Overall Study Decision by sponsor	0	3	19	7	3
Overall Study Withdrawal by Subject	1	1	2	2	0
Overall Study Death	3	5	8	18	1
Overall Study Lost to Follow-up	0	0	0	1	0

Baseline Characteristics

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 2: Bemarituzumab Dose 2 With Docetaxel n=29 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=28 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=4 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Total n=74 Participants Total of all reporting groups
Age, Continuous	64.0 years STANDARD_DEVIATION 4.5 • n=5 Participants	65.9 years STANDARD_DEVIATION 8.5 • n=7 Participants	65.3 years STANDARD_DEVIATION 6.2 • n=5 Participants	63.0 years STANDARD_DEVIATION 8.2 • n=4 Participants	63.0 years STANDARD_DEVIATION 7.9 • n=21 Participants	64.3 years STANDARD_DEVIATION 7.2 • n=8 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants	8 Participants n=4 Participants	0 Participants n=21 Participants	12 Participants n=8 Participants
Sex: Female, Male Male	4 Participants n=5 Participants	7 Participants n=7 Participants	27 Participants n=5 Participants	20 Participants n=4 Participants	4 Participants n=21 Participants	62 Participants n=8 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=8 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	4 Participants n=5 Participants	9 Participants n=7 Participants	27 Participants n=5 Participants	27 Participants n=4 Participants	4 Participants n=21 Participants	71 Participants n=8 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race/Ethnicity, Customized Asian	2 Participants n=5 Participants	4 Participants n=7 Participants	12 Participants n=5 Participants	12 Participants n=4 Participants	3 Participants n=21 Participants	33 Participants n=8 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race/Ethnicity, Customized White	2 Participants n=5 Participants	4 Participants n=7 Participants	14 Participants n=5 Participants	11 Participants n=4 Participants	1 Participants n=21 Participants	32 Participants n=8 Participants
Race/Ethnicity, Customized Other	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race/Ethnicity, Customized Missing	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	5 Participants n=4 Participants	0 Participants n=21 Participants	7 Participants n=8 Participants

PRIMARY outcome

Timeframe: Day 1 to Day 21 of Cycle 1 (each cycle was 21 days)

Population: The safety analysis set included all participants who received at least one dose of bemarituzumab.

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=4 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Number of Participants Who Experienced a Dose Limiting Toxicity (DLT): Parts 1 and 4	0 Participants	1 Participants	0 Participants	—	—

PRIMARY outcome

Timeframe: Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks.

Population: The safety analysis set included all participants who received at least one dose of bemarituzumab.

An AE was defined as any untoward medical occurrence in a clinical trial participants. TEAEs were any AE that started on or after receiving the first dose of investigational product and up to 28 days after the last dose of investigational product or the end of study date, whichever is earlier. Treatment-related TEAEs were those considered possibly related to study treatment by the investigator. Any clinically significant changes in electrocardiograms, vital signs, physical examination with a neurological assessment, clinical laboratory tests, and visual acuity were recorded as TEAEs. A serious TEAE resulted in death, was immediately life threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event. AEs of special interest (AESIs) were ocular events of any CTCAE grade or seriousness occurring up to 100 days after the last dose of bemarituzumab.

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=29 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=28 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=4 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Any treatment-related SAE	0 Participants	0 Participants	2 Participants	0 Participants	2 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Any TEAE	4 Participants	9 Participants	29 Participants	25 Participants	4 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Any SAE	4 Participants	5 Participants	16 Participants	8 Participants	4 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Any treatment-related TEAE	3 Participants	9 Participants	21 Participants	16 Participants	2 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Any AESI	2 Participants	6 Participants	17 Participants	9 Participants	2 Participants

SECONDARY outcome

Timeframe: Parts 1, 2, 3, and 4: Cycles 1 and 2 pre-dose, 0.25, 3, 6, 24, 72, 168, 336, 504 (except Part 3) hours post-dose

Population: The PK analysis set included all participants who received at least one dose of bemarituzumab and had at least one PK sample collected. Participants with data available at each timepoint are presented.

Bemarituzumab serum concentrations with values below the limit of quantification were set to zero for analysis. Pharmacokinetic (PK) parameters were determined from the time concentration profile using noncompartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=29 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=25 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=3 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Area Under the Serum Drug Concentration-time Curve From Time 0 to End of Dosing Interval (AUCtau) of Bemarituzumab Cycle 1	3370 day*mcg/mL Interval 2400.0 to 4880.0	5300 day*mcg/mL Interval 3830.0 to 6870.0	3920 day*mcg/mL Interval 2290.0 to 6470.0	2800 day*mcg/mL Interval 1360.0 to 4820.0	3020 day*mcg/mL Interval 2000.0 to 3270.0
Area Under the Serum Drug Concentration-time Curve From Time 0 to End of Dosing Interval (AUCtau) of Bemarituzumab Cycle 2	2610 day*mcg/mL Interval 2160.0 to 4810.0	4850 day*mcg/mL Interval 1190.0 to 7290.0	4000 day*mcg/mL Interval 1200.0 to 10300.0	3580 day*mcg/mL Interval 1880.0 to 5970.0	2340 day*mcg/mL Interval 1470.0 to 3200.0

SECONDARY outcome

Timeframe: Parts 1, 2, 3, and 4: Cycles 1 and 2 pre-dose, 0.25, 3, 6, 24, 72, 168, 336, 504 (except Part 3) hours post-dose

Bemarituzumab serum concentrations with values below the limit of quantification were set to zero for analysis. PK parameters were determined from the time concentration profile using noncompartmental analysis.

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=29 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=25 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=3 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Maximum Observed Serum Concentration (Cmax) of Bemarituzumab Cycle 1	599 mcg/mL Interval 457.0 to 751.0	746 mcg/mL Interval 627.0 to 896.0	646 mcg/mL Interval 338.0 to 956.0	398 mcg/mL Interval 238.0 to 1430.0	561 mcg/mL Interval 463.0 to 564.0
Maximum Observed Serum Concentration (Cmax) of Bemarituzumab Cycle 2	379 mcg/mL Interval 358.0 to 599.0	715 mcg/mL Interval 595.0 to 910.0	601 mcg/mL Interval 314.0 to 845.0	532 mcg/mL Interval 314.0 to 811.0	322 mcg/mL Interval 235.0 to 409.0

SECONDARY outcome

Timeframe: Pre-dose Cycle 2 Day 1 and Cycle 3 day 1

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=3 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=21 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=26 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=3 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Observed Concentration at the End of a Dose Interval (Ctrough) of Bemarituzumab Pre-dose Cycle 3 Day 1	79.1 mcg/mL Interval 33.9 to 112.0	149 mcg/mL Interval 45.0 to 201.0	111 mcg/mL Interval 30.6 to 169.0	140 mcg/mL Interval 29.3 to 271.0	69.2 mcg/mL Interval 69.2 to 69.2
Observed Concentration at the End of a Dose Interval (Ctrough) of Bemarituzumab Pre-dose Cycle 2 Day 1	51.5 mcg/mL Interval 25.8 to 96.6	93.7 mcg/mL Interval 40.2 to 175.0	88.9 mcg/mL Interval 50.5 to 154.0	147 mcg/mL Interval 10.1 to 554.0	29.9 mcg/mL Interval 25.3 to 32.5

SECONDARY outcome

Timeframe: Every 6 (+/- 1) weeks from the first dose of bemarituzumab (cycle 1 day 1) up to week 54, then every 12 (+/- 2 weeks), up to the end of the long term follow-up (LTFU) period (median time on study was approximately 21 weeks)

Population: The safety analysis set included all participants who received at least one dose of bemarituzumab.

OR was defined as the best overall response of confirmed complete response (CR) or confirmed partial response (PR) as defined by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). CR: disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \<10 mm. All lymph nodes must have been non-pathological in size (\< 10 mm). PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=29 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=28 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=4 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Percentage of Participants Who Achieved an Objective Response (OR)	0.0 percentage of participants Interval 0.0 to 60.2	22.2 percentage of participants Interval 2.8 to 60.0	10.3 percentage of participants Interval 2.2 to 27.4	0.0 percentage of participants Interval 0.0 to 12.3	25.0 percentage of participants Interval 0.6 to 80.6

SECONDARY outcome

Timeframe: Every 6 (+/- 1) weeks from the first dose of bemarituzumab (cycle 1 day 1) up to week 54, then every 12 (+/- 2 weeks), up to the end of the LTFU period (median time on study was approximately 21 weeks)

Population: The safety analysis set included all participants who received at least one dose of bemarituzumab. Only participants who had achieved OR were evaluated for DOR.

DOR was defined as the time from the first documentation of OR (determined by the investigator per RECIST v1.1) until first documentation of disease progression or death due to any cause, whichever occurred first. DOR was censored at the last evaluable post-baseline tumor assessment prior to subsequent anticancer therapy; otherwise, at date of first documentation of OR (i.e., assigned a one-day interval).

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=2 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=3 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=1 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Duration of Response (DOR)	—	5.5 months Interval 2.8 to Upper confidence interval (CI) was not calculable due to insufficient event data occurring above the median.	2.8 months Interval 2.8 to Upper CI was not calculable due to insufficient event data occurring above the median.	—	4.5 months CIs were not calculable due to only 1 participant achieving OR.

SECONDARY outcome

Population: The safety analysis set included all participants who received at least one dose of bemarituzumab.

DCR was defined as the percentage of participants documented to have a CR, PR or stable disease (SD) per RECIST v1.1. CR: disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have had a reduction in short axis to \<10 mm. All lymph nodes must have been non-pathological in size (\< 10 mm). PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD: at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an increase of at least 5 mm. Unequivocal progression of existing non-target lesions.

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=29 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=28 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=4 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Disease Control Rate (DCR)	75.0 percentage of participants Interval 19.4 to 99.4	66.7 percentage of participants Interval 29.9 to 92.5	65.5 percentage of participants Interval 45.7 to 82.1	53.6 percentage of participants Interval 33.9 to 72.5	75.0 percentage of participants Interval 19.4 to 99.4

SECONDARY outcome

Timeframe: Participants completed the LTFU for survival every 3 months ± 1 month after the safety follow-up visit (at 28 days after the last dose of bemarituzumab), up to the end of the study. Median time on study was approximately 21 weeks

Population: The safety analysis set included all participants who received at least one dose of bemarituzumab.

PFS was defined as the time from date of first dose of investigational product until the first documentation of radiologic disease progression or death due to any cause, whichever occurred first, in the absence of subsequent anticancer therapy. PFS was censored at the last evaluable post-baseline tumor assessment prior to subsequent anticancer therapy; otherwise, at first dose of investigational product. Progression was based on RECIST v1.1 criteria. PD: at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an increase of at least 5 mm. Unequivocal progression of existing non-target lesions.

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=29 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=28 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=4 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Progression-free Survival (PFS)	4.2 months Interval 1.2 to Upper CI was not calculable due to insufficient event data occurring above the median.	4.2 months Interval 1.4 to 10.8	4.0 months Interval 1.4 to 4.4	1.8 months Interval 1.3 to 2.6	5.6 months Interval 1.3 to Upper CI was not calculable due to insufficient event data occurring above the median.

SECONDARY outcome

Population: The safety analysis set included all participants who received at least one dose of bemarituzumab.

OS was defined as the time from the date of first dose of investigational product until event of death due to any cause through the analysis cutoff date. Participants still alive were censored at the date last known to be alive through the analysis cutoff date.

Outcome measures

Outcome measures
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 Participants Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 Participants Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=29 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=28 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=4 Participants Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Overall Survival (OS)	6.0 months Interval 5.6 to Upper CI was not calculable due to insufficient event data occurring above the median.	12.8 months Interval 3.3 to Upper CI was not calculable due to insufficient event data occurring above the median.	NA months Interval 9.1 to Median and upper CI were not calculable due to fewer than 50% events.	5.4 months Interval 2.8 to 8.0	NA months Interval 3.5 to Median and upper CI were not calculable due to fewer than 50% events.

Adverse Events

Part 1: Bemarituzumab Dose 1 With Docetaxel

Serious events: 4 serious events

Other events: 4 other events

Deaths: 3 deaths

Part 1: Bemarituzumab Dose 2 With Docetaxel

Serious events: 5 serious events

Other events: 9 other events

Deaths: 5 deaths

Part 2: Bemarituzumab Dose 2 With Docetaxel

Serious events: 16 serious events

Other events: 26 other events

Deaths: 8 deaths

Part 3: Bemarituzumab Dose 1

Serious events: 8 serious events

Other events: 23 other events

Deaths: 18 deaths

Part 4: Bemarituzumab Dose 2 First-line Combination Therapy

Serious events: 4 serious events

Other events: 4 other events

Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 participants at risk Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 participants at risk Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 2: Bemarituzumab Dose 2 With Docetaxel n=29 participants at risk Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=28 participants at risk Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=4 participants at risk Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Blood and lymphatic system disorders Febrile neutropenia	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	13.8% 4/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Blood and lymphatic system disorders Neutropenia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Cardiac disorders Acute myocardial infarction	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Cardiac disorders Cardiac tamponade	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Cardiac disorders Pericardial effusion	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Cardiac disorders Pericarditis malignant	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Corneal epithelium defect	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Visual acuity reduced	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Ileus	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Melaena	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Oesophageal stenosis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Asthenia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders General physical health deterioration	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Infusion site extravasation	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Mucosal inflammation	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Hepatobiliary disorders Cholecystitis	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Bronchopulmonary aspergillosis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations COVID-19	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Infectious pleural effusion	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Neutropenic infection	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Neutropenic sepsis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Pneumonia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.3% 3/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Pneumonia bacterial	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Pneumonia pneumococcal	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Sepsis	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Investigations C-reactive protein increased	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Nervous system disorders Cerebral disorder	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Nervous system disorders Trigeminal neuralgia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Renal and urinary disorders Renal colic	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Vascular disorders Shock	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Vascular disorders Superior vena cava syndrome	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.

Other adverse events

Other adverse events
Measure	Part 1: Bemarituzumab Dose 1 With Docetaxel n=4 participants at risk Participants received multiple IV doses of bemarituzumab dose level 1 and IV docetaxel (cycle length = 21 days).	Part 1: Bemarituzumab Dose 2 With Docetaxel n=9 participants at risk Participants received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 2: Bemarituzumab Dose 2 With Docetaxel n=29 participants at risk Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 and IV docetaxel (cycle length = 21 days).	Part 3: Bemarituzumab Dose 1 n=28 participants at risk Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 1 (cycle length = 14 days).	Part 4: Bemarituzumab Dose 2 First-line Combination Therapy n=4 participants at risk Participants who had an overexpression of FGFR2b received multiple IV doses of bemarituzumab dose level 2 in combination with pembrolizumab, carboplatin and either paclitaxel or nab-paclitaxel (cycle length = 21 days).
Blood and lymphatic system disorders Anaemia	50.0% 2/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	20.7% 6/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Blood and lymphatic system disorders Iron deficiency anaemia	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Blood and lymphatic system disorders Neutropenia	50.0% 2/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	17.2% 5/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Cardiac disorders Arrhythmia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Cardiac disorders Tachycardia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Ear and labyrinth disorders Vertigo	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Acute macular neuroretinopathy	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Blepharitis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	17.2% 5/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.7% 3/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Cataract	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Conjunctival hyperaemia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Corneal disorder	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	33.3% 3/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Corneal epithelium defect	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.3% 3/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Corneal opacity	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Detachment of retinal pigment epithelium	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Dry eye	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	14.3% 4/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Keratitis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.3% 3/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Keratopathy	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	22.2% 2/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	34.5% 10/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	14.3% 4/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Limbal stem cell deficiency	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	13.8% 4/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Meibomian gland dysfunction	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Retinal drusen	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Retinal haemorrhage	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Vision blurred	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Eye disorders Visual acuity reduced	75.0% 3/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	66.7% 6/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	51.7% 15/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	32.1% 9/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	50.0% 2/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Constipation	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	22.2% 2/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Diarrhoea	50.0% 2/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	22.2% 2/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	27.6% 8/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Dry mouth	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	14.3% 4/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Dysphagia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Enteritis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Gingival pain	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Haemorrhoids	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Nausea	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	14.3% 4/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Odynophagia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Stomatitis	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	22.2% 2/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	13.8% 4/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Toothache	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Gastrointestinal disorders Vomiting	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Asthenia	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	34.5% 10/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Fatigue	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	22.2% 2/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.7% 3/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Generalised oedema	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Malaise	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Mucosal inflammation	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	13.8% 4/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Non-cardiac chest pain	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Oedema peripheral	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
General disorders Pyrexia	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.7% 3/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Hepatobiliary disorders Liver injury	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations COVID-19	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Influenza	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Oral fungal infection	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Paronychia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Pneumonia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	22.2% 2/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Tooth abscess	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Infections and infestations Upper respiratory tract infection	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Investigations Alanine aminotransferase increased	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Investigations Aspartate aminotransferase increased	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Investigations Weight decreased	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.7% 3/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Decreased appetite	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	22.2% 2/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	27.6% 8/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	14.3% 4/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hypercalcaemia	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.7% 3/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hyperkalaemia	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hypoalbuminaemia	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Nervous system disorders Dizziness	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Nervous system disorders Dysgeusia	50.0% 2/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Nervous system disorders Headache	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.7% 3/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Nervous system disorders Spinal cord compression	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Psychiatric disorders Insomnia	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Renal and urinary disorders Haematuria	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Renal and urinary disorders Renal impairment	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	33.3% 3/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.3% 3/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.7% 3/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	21.4% 6/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	22.2% 2/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Lung opacity	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Pharyngeal erythema	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Respiratory failure	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Respiratory, thoracic and mediastinal disorders Upper respiratory tract inflammation	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Skin and subcutaneous tissue disorders Alopecia	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	22.2% 2/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	10.3% 3/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Skin and subcutaneous tissue disorders Nail discolouration	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Skin and subcutaneous tissue disorders Nail dystrophy	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	7.1% 2/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Skin and subcutaneous tissue disorders Rash	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.4% 1/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Vascular disorders Deep vein thrombosis	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	11.1% 1/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Vascular disorders Hypertension	25.0% 1/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.
Vascular disorders Hypotension	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/9 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	6.9% 2/29 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	3.6% 1/28 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.	0.00% 0/4 • For all cause mortality, from first dose of bemarituzumab until end of study; median (min, max) time on study was 20.79 [1.9, 83.7] weeks. For serious AEs and other AEs, Day 1 of cycle 1 to 100 days after the last dose of study treatment or end of study date, whichever occurred earlier (Parts 1, 2, and 4 cycle length = 21 days; Part 3 cycle length = 14 days). Median treatment duration was 6.2 weeks. The safety analysis set included all participants who received at least one dose of bemarituzumab.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
Publication restrictions are in place

Restriction type: OTHER